SUNSHINE PHARMA(06887) Files with CSRC for Proposed Implementation of Full Circulation of H Shares
Sunshine Pharma (06887) announced that on September 23, 2026, the Company submitted a filing application to the China Securities Regulatory Commission (CSRC) for the conversion of 38,921,700 domestic shares of the Company held by certain shareholders of the Company into H shares of the Company (the Application), representing approximately 6.75% of the total issued share capital of the Company as at the date of this announcement (Full Circulation of H Shares).
SUNSHINE PHARMA (06887) announced that on September 23, 2026, the Company submitted a filing application to the CSRC in respect of the conversion of 38,921,700 Domestic Shares of the Company held by certain shareholders of the Company into H Shares of the Company (the Application), representing approximately 6.75% of the total issued share capital of the Company as at the date of this announcement (Full Circulation of H Shares).
Upon obtaining all relevant approvals (including the filing with the CSRC and approval from the Stock Exchange) and compliance with all applicable laws, rules and regulations, the relevant Domestic Shares will be converted into H Shares, and the Company will apply to the Stock Exchange for the listing of, and permission to deal in, such H Shares on the Main Board of the Stock Exchange (the Conversion and Listing).
Pursuant to the Articles of Association of the Company and applicable PRC laws, the Company is not required to convene a shareholders' general meeting to approve the Full Circulation of H Shares and the Conversion and Listing.
As at the date of this announcement, the Application of the Company has not yet been accepted by the CSRC, and the details of the implementation of the Conversion and Listing plan have not yet been finalized. The Company will make further announcement(s) in relation to the progress of the Full Circulation of H Shares and the Conversion and Listing as and when appropriate in accordance with the requirements of the Listing Rules.
Related Articles

Sunflower Pharmaceutical Group (002737.SZ) plans to acquire 100% equity of Dongxu Pharmaceutical.

GOFINTECH QUANT (00290) grants a total of 74.192 million share awards.

TIAN TU CAPITAL (01973): Subsidiary intends to subscribe for equity interests in Topos AI Infra Holdings and Topos AI Infra Investments, with a total commitment of US$25 million.
Sunflower Pharmaceutical Group (002737.SZ) plans to acquire 100% equity of Dongxu Pharmaceutical.

GOFINTECH QUANT (00290) grants a total of 74.192 million share awards.

TIAN TU CAPITAL (01973): Subsidiary intends to subscribe for equity interests in Topos AI Infra Holdings and Topos AI Infra Investments, with a total commitment of US$25 million.






